Article title: Daridorexant as a novel pharmacotherapeutic approach in insomnia: a systematic review and meta-analysis
Authors: Dutta S, Singhal S, Shah R, et al.
Journal: EXPERT OPINION ON DRUG SAFETY
DOI: https://doi.org/10.1080/14740338.2023.2243217
When this article was first published online, there were some errors, which are now corrected as below.
In page 7, first paragraph, “Similarly, the data of efficacy parameters for 50 mg were available from two RCTs (Dauvilliers et al., 2020, and NCT03545191) for 1 month however data for 3 months were not available from any of the included RCTs.”
Is now modified as
“Similarly, the data of efficacy parameters for 50 mg were available from two RCTs (Dauvilliers et al., 2020 and NCT03545191) for 1 month however data for 3 months was available from only one RCT (NCT03545191), hence it could not be included for pooled analysis.”
In page 12, right column second paragraph, second point, “The drug is under trials for specific conditions like obstructive sleep apnea, chronic obstructive pulmonary disease, renal and hepatic impairment, abuse potential and drug–drug interactions for generating additional evidence for long-term use of this molecule [14].”
Is now modified as
“On further exploring the https://clinicaltrials.gov/ database, the drug is also under trials for several specific conditions like obstructive sleep apnea, chronic obstructive pulmonary disease, renal and hepatic impairment, abuse potential, pharmacokinetic studies among 10 to < 18 years of age, insomnia and comorbid nocturia, insomnia in patients with mild cognitive impairment and mild to moderate Alzheimer disease, post-traumatic stress disorder, nighttime body posture, the noise level required to wake up, and the ability to remember words previously presented and drug-drug interactions for generating additional evidence for long-term use of this molecule [14].”
In table 1, Serial number 4, under “Study intervention regimen (number of patients)”, the data 12 weeks is changed to 40 weeks.